Results 181 to 190 of about 22,552 (237)
Clinical and laboratory practice for lupus anticoagulant testing: An International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey [PDF]
Journal of Thrombosis and Haemostasis, 2019 Background Current guidelines have contributed to more uniformity in the performance and interpretation of lupus anticoagulant (LA) testing. However, points to reconsider include testing for LA in patients on anticoagulation, cut-off values, and ...
Hannah Cohen +2 more
exaly +2 more sources
Update of the guidelines for lupus anticoagulant detection
Journal of Thrombosis and Haemostasis, 2009 One of the conclusions of the subcommittee meeting on Lupus Anticoagulant/Phospholipid dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on Lupus Anticoagulant (LA) detection.
Vittorio Pengo +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
LUPUS ANTICOAGULANT IN PREGNANCY
The Lancet, 1984summaryIn a group of 10 women with circulating lupus anticoagulant 25 intrauterine deaths were previously documented in the nine multigravidae. The presence of lupus anticoagulant activity was confirmed by showing prolongation of the activated partial thromboplastin time and kaolin clotting time with failure of correction of the prolongation on ...
Prentice, RL +5 more
openaire +6 more sources
Blood Reviews, 1991
Acquired antibodies to phospholipids form a heterogeneous group, which may be detected in vitro by the inhibition of phospholipid dependent tests of coagulation (lupus anticoagulant) and also by immunological assays, such that a combined approach is required for their reliable detection.
M D, Creagh, M, Greaves
openaire +2 more sources
Acquired antibodies to phospholipids form a heterogeneous group, which may be detected in vitro by the inhibition of phospholipid dependent tests of coagulation (lupus anticoagulant) and also by immunological assays, such that a combined approach is required for their reliable detection.
M D, Creagh, M, Greaves
openaire +2 more sources
Arthritis & Rheumatism, 1976
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
M, Boxer, L, Ellman, A, Carvalho
openaire +2 more sources
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
M, Boxer, L, Ellman, A, Carvalho
openaire +2 more sources
Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI)
Lupus, 2012Results for lupus anticoagulant (LA) are expressed as ratio of patient-to-normal clotting times (LA-ratio) according to the equation LA-ratio = (Patient Clotting time /Normal Clotting time ).
Tripodi A +2 more
openaire +2 more sources
Testing for Lupus Anticoagulants
Seminars in Thrombosis and Hemostasis, 2022AbstractLupus anticoagulant (LA) is one of the three criteria antiphospholipid antibodies (aPLs) employed in classification, and by default diagnosis, of antiphospholipid syndrome (APS). Detection of LA is not via calibrated assays but is based on functional behavior of the antibodies in a medley of coagulation assays.
openaire +2 more sources
The challenges of lupus anticoagulants
Expert Review of Hematology, 2016The term "lupus anticoagulant" (LA) refers to a heterogeneous group of immunoglobulins behaving as acquired in vitro inhibitors of coagulation. These antibodies, namely anti-β2GPI and anti-prothrombin antibodies, induce the in vitro elongation of clotting time interfering with phospholipid-dependent coagulation cofactors. Positive LA is associated with
Chighizola, Cecilia Beatrice +5 more
openaire +2 more sources
Lupus Anticoagulant and Stroke
Archives of Neurology, 1987To the Editor. —Tabachnik-Schor and Lipton's 1 recent report of a case of nonvasculitic cerebral infarction associated with a lupuslike anticoagulant (LA) suggests that their case is the first without "other causes of vasculopathy." Several features of their patient's case do not appear to support their conclusion. Their patient's skin biopsy specimen
S R, Levine, K M, Welch
openaire +2 more sources
The Lupus Anticoagulant Paradox
Seminars in Thrombosis and Hemostasis, 2017AbstractLupus anticoagulant (LA) represents the most enigmatic antibody population in patients with antiphospholipid syndrome and represents a paradox that is still unsolved. This class of antiphospholipid antibody causes a phospholipid-dependent prolongation of the clotting time but is associated with an increased risk of thrombosis and pregnancy ...
Jessica E, Molhoek +2 more
openaire +2 more sources